Prospects for redox-based therapy in neurodegenerative diseases
Accumulating evidence supports a primary role for perturbations in redox metabolism in the pathogenesis of many neurodegenerative diseases. This evidence derives mainly from molecular genetic analysis, direct observation from post-mortem human brain, and biochemical, pathologic, and therapeutic stud...
Gespeichert in:
| Veröffentlicht in: | Neurotoxicity research 2000-06, Vol.2 (2-3), p.229-237 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 237 |
|---|---|
| container_issue | 2-3 |
| container_start_page | 229 |
| container_title | Neurotoxicity research |
| container_volume | 2 |
| creator | Friedlich, A L Beal, M F |
| description | Accumulating evidence supports a primary role for perturbations in redox metabolism in the pathogenesis of many neurodegenerative diseases. This evidence derives mainly from molecular genetic analysis, direct observation from post-mortem human brain, and biochemical, pathologic, and therapeutic studies in transgenic and other animal models of neurodegeneration. We review here the evidence for redox-mediated pathogenesis in neurodegenerative diseases. The emerging class of redox-based therapeutic agents is then discussed. Drugs of this class are distinguished by their proximate effect, which is oxidative and not phosphorylative. |
| doi_str_mv | 10.1007/BF03033796 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20183959</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20183959</sourcerecordid><originalsourceid>FETCH-LOGICAL-c246t-75b071d1850cd362f2511c4bf63d91cb7f60ec979ff191573404e9dab9c1e5853</originalsourceid><addsrcrecordid>eNpFkE1Lw0AURQdRbK1u_AGSlQshOm--ZyVarAoFXeg6JDNvNNImcSYR---NtNDVuzwOF-4h5BzoNVCqb-4XlFPOtVUHZApCq5xLJg7HTJnNjWBmQk5S-qKUgVT6mExAaaON4FNy-xrb1KHrUxbamEX07W9elQl91n9iLLtNVjdZg0NsPX5gM776-gczXyccqXRKjkK5Sni2uzPyvnh4mz_ly5fH5_ndMndMqD7XsqIaPBhJneeKBSYBnKiC4t6Cq3RQFJ3VNgSwIDUXVKD1ZWUdoDSSz8jltreL7feAqS_WdXK4WpUNtkMqGAXDrbQjeLUF3TgsRQxFF-t1GTcF0OJfV7HXNcIXu9ahWqPfozs__A-SqGRa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20183959</pqid></control><display><type>article</type><title>Prospects for redox-based therapy in neurodegenerative diseases</title><source>Springer Online Journals Complete</source><creator>Friedlich, A L ; Beal, M F</creator><creatorcontrib>Friedlich, A L ; Beal, M F</creatorcontrib><description>Accumulating evidence supports a primary role for perturbations in redox metabolism in the pathogenesis of many neurodegenerative diseases. This evidence derives mainly from molecular genetic analysis, direct observation from post-mortem human brain, and biochemical, pathologic, and therapeutic studies in transgenic and other animal models of neurodegeneration. We review here the evidence for redox-mediated pathogenesis in neurodegenerative diseases. The emerging class of redox-based therapeutic agents is then discussed. Drugs of this class are distinguished by their proximate effect, which is oxidative and not phosphorylative.</description><identifier>ISSN: 1029-8428</identifier><identifier>EISSN: 1476-3524</identifier><identifier>DOI: 10.1007/BF03033796</identifier><identifier>PMID: 16787843</identifier><language>eng</language><publisher>United States</publisher><ispartof>Neurotoxicity research, 2000-06, Vol.2 (2-3), p.229-237</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c246t-75b071d1850cd362f2511c4bf63d91cb7f60ec979ff191573404e9dab9c1e5853</citedby><cites>FETCH-LOGICAL-c246t-75b071d1850cd362f2511c4bf63d91cb7f60ec979ff191573404e9dab9c1e5853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16787843$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Friedlich, A L</creatorcontrib><creatorcontrib>Beal, M F</creatorcontrib><title>Prospects for redox-based therapy in neurodegenerative diseases</title><title>Neurotoxicity research</title><addtitle>Neurotox Res</addtitle><description>Accumulating evidence supports a primary role for perturbations in redox metabolism in the pathogenesis of many neurodegenerative diseases. This evidence derives mainly from molecular genetic analysis, direct observation from post-mortem human brain, and biochemical, pathologic, and therapeutic studies in transgenic and other animal models of neurodegeneration. We review here the evidence for redox-mediated pathogenesis in neurodegenerative diseases. The emerging class of redox-based therapeutic agents is then discussed. Drugs of this class are distinguished by their proximate effect, which is oxidative and not phosphorylative.</description><issn>1029-8428</issn><issn>1476-3524</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNpFkE1Lw0AURQdRbK1u_AGSlQshOm--ZyVarAoFXeg6JDNvNNImcSYR---NtNDVuzwOF-4h5BzoNVCqb-4XlFPOtVUHZApCq5xLJg7HTJnNjWBmQk5S-qKUgVT6mExAaaON4FNy-xrb1KHrUxbamEX07W9elQl91n9iLLtNVjdZg0NsPX5gM776-gczXyccqXRKjkK5Sni2uzPyvnh4mz_ly5fH5_ndMndMqD7XsqIaPBhJneeKBSYBnKiC4t6Cq3RQFJ3VNgSwIDUXVKD1ZWUdoDSSz8jltreL7feAqS_WdXK4WpUNtkMqGAXDrbQjeLUF3TgsRQxFF-t1GTcF0OJfV7HXNcIXu9ahWqPfozs__A-SqGRa</recordid><startdate>20000601</startdate><enddate>20000601</enddate><creator>Friedlich, A L</creator><creator>Beal, M F</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20000601</creationdate><title>Prospects for redox-based therapy in neurodegenerative diseases</title><author>Friedlich, A L ; Beal, M F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c246t-75b071d1850cd362f2511c4bf63d91cb7f60ec979ff191573404e9dab9c1e5853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Friedlich, A L</creatorcontrib><creatorcontrib>Beal, M F</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Neurotoxicity research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Friedlich, A L</au><au>Beal, M F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prospects for redox-based therapy in neurodegenerative diseases</atitle><jtitle>Neurotoxicity research</jtitle><addtitle>Neurotox Res</addtitle><date>2000-06-01</date><risdate>2000</risdate><volume>2</volume><issue>2-3</issue><spage>229</spage><epage>237</epage><pages>229-237</pages><issn>1029-8428</issn><eissn>1476-3524</eissn><abstract>Accumulating evidence supports a primary role for perturbations in redox metabolism in the pathogenesis of many neurodegenerative diseases. This evidence derives mainly from molecular genetic analysis, direct observation from post-mortem human brain, and biochemical, pathologic, and therapeutic studies in transgenic and other animal models of neurodegeneration. We review here the evidence for redox-mediated pathogenesis in neurodegenerative diseases. The emerging class of redox-based therapeutic agents is then discussed. Drugs of this class are distinguished by their proximate effect, which is oxidative and not phosphorylative.</abstract><cop>United States</cop><pmid>16787843</pmid><doi>10.1007/BF03033796</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1029-8428 |
| ispartof | Neurotoxicity research, 2000-06, Vol.2 (2-3), p.229-237 |
| issn | 1029-8428 1476-3524 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20183959 |
| source | Springer Online Journals Complete |
| title | Prospects for redox-based therapy in neurodegenerative diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T23%3A44%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prospects%20for%20redox-based%20therapy%20in%20neurodegenerative%20diseases&rft.jtitle=Neurotoxicity%20research&rft.au=Friedlich,%20A%20L&rft.date=2000-06-01&rft.volume=2&rft.issue=2-3&rft.spage=229&rft.epage=237&rft.pages=229-237&rft.issn=1029-8428&rft.eissn=1476-3524&rft_id=info:doi/10.1007/BF03033796&rft_dat=%3Cproquest_cross%3E20183959%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20183959&rft_id=info:pmid/16787843&rfr_iscdi=true |